ReviewDialogues in clinical neuroscience2014
Proteomics, metabolomics, and protein interactomics in the characterization of the molecular features of major depressive disorder.
Review in Dialogues in clinical neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Metabolomics Profile in Depression: A Pooled Analysis of 230 Metabolic Markers in 5283 Cases With Depression and 10,145 Controls.Biological psychiatry · 2020Pooled it
- Trial
- Can targeted metabolomics predict depression recovery? Results from the CO-MED trial.Translational psychiatry · 2019Trial
- Metabolomics reveal distinct molecular pathways associated with future risk of Crohn's Disease.Gut microbes · 2025Article
- Optic disc morphometrics as a potential ocular biomarker for depression: evidence from two cross-sectional cohort studies.Translational psychiatry · 2025Article
- Plasma Lyso-PE 22:6 and Lyso-PE 20:4 are associated with development of mild to moderate depression revealed by metabolomics: a pilot study.BMC psychiatry · 2025Article
- Protein associations and protein-metabolite interactions with depressive symptoms and the p-factor.Translational psychiatry · 2025Article
- The Restoration of Energy Pathways Indicates the Efficacy of Ketamine Treatment in Depression: A Metabolomic Analysis.CNS neuroscience & therapeutics · 2025Article
- Medwakh smoking induces alterations in salivary proteins and cytokine expression: a clinical exploratory proteomics investigation.Clinical proteomics · 2025Article
- LC-HRMS Lipidomic Fingerprints in Serbian Cohort of Schizophrenia Patients.International journal of molecular sciences · 2024Article
- Vitamin D-binding protein in plasma microglia-derived extracellular vesicles as a potential biomarker for major depressive disorder.Genes & diseases · 2024Article
- Translational bioinformatics and data science for biomarker discovery in mental health: an analytical review.Briefings in bioinformatics · 2024Review
- Untargeted Lipidomics Study of Bipolar Disorder Patients in Serbia.International journal of molecular sciences · 2023Article
- Cell-Type-Specific Neuroproteomics of Synapses.Biomolecules · 2023Review
- Connecting Dots between Mitochondrial Dysfunction and Depression.Biomolecules · 2023Review
- Discovery and replication of blood-based proteomic signature of PTSD in 9/11 responders.Translational psychiatry · 2023Article
- Approach strategies and application of metabolomics to biotechnology in plants.Frontiers in plant science · 2023Review
- The PROVIT Study-Effects of Multispecies Probiotic Add-on Treatment on Metabolomics in Major Depressive Disorder-A Randomized, Placebo-Controlled Trial.Metabolites · 2022Article
- Gut Microbiota Metabolites in Major Depressive Disorder-Deep Insights into Their Pathophysiological Role and Potential Translational Applications.Metabolites · 2022Review
- Branched-chain amino acids linked to depression in young adults.Frontiers in neuroscience · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Omics technologies emerged as complementary strategies to genomics in the attempt to understand human illnesses. In general, proteomics technologies emerged earlier than those of metabolomics for major depressive disorder (MDD) research, but both are driven by the identification of proteins and/or metabolites that can delineate a comprehensive characterization of MDD's molecular mechanisms, as well as lead to the identification of biomarker candidates of all types-prognosis, diagnosis, treatment, and patient stratification. Also, one can explore protein and metabolite interactomes in order to pinpoint additional molecules associated with the disease that had not been picked up initially. Here, results and methodological aspects of MDD research using proteomics, metabolomics, and protein interactomics are reviewed, focusing on human samples.
Indexed as
Identifiers
24733971PMC3984892What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.